The overall goal of this specimen procurement core is the collection, maintenance, and distribution of high quality biologic samples from a spectrum of prostate cancer and control patients, along with collection of accurate linked clinical and pathologic data on these samples. The Robert H. Lurie Comprehensive Cancer Center's Specialized Program of Research Excellence (SPORE) in prostate cancer consists of three prostate cancer treatment centers;Northwestern Memorial Hospital (NMH), Evanston Northwestern Healthcare (ENH; principally Evanston Hospital), and the Jesse Brown Veterans Administration Medical Center (VA). The University of Chicago is now integrated into our SPORE, and in the future will contribute biologic samples as well. Because these institutions see large numbers of new prostate cancer patients from a spectrum of socioeconomic and ethnic groups, with over 500 annual radical prostate ctomies performed, our access to patient derived tissues for research is high and diverse. NMH, the VA, and ENH have successfully implemented sample procurement to support the prostate SPORE efforts and collectively, these facilities have procured samples on approximately 1900 patients since 2001. Samples (tissue, serum, DNA, RNA, and TMAs) and data have been provided for 48 studies to date. The Robert H. Lurie C omprehensive Cancer Center Pathology Core Facility (RHLCCC-PCF), a shared resource of the RHLCCC, is independent of but complements the tissue procurement by providing research histology expertise. This core will continue the collection of fixed embedded and fresh frozen tissues, urine, blood and blood components, as well as the acquisition and database storage of essential pathologic and clinical information needed for conducting translational research. Additionally, the facility has constructed numerous tissue microarrays to suit the needs of SPORE investigators. This resource will benefit not only our SPORE investigators, but will facilitate research activities of scientists within and outside the parent institution. T his process is supervised by a Sample Review and Disbursement Committee, (including physicians, pathologists and a patient advocate), the SPORE Executive Committee, and reviewed by the individual Institutional Review Boards (IRBs) on an annual basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090386-10
Application #
8444304
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
10
Fiscal Year
2013
Total Cost
$236,038
Indirect Cost
$47,872
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Pascal, Laura E; Masoodi, Khalid Z; O'Malley, Katherine J et al. (2015) 5?-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol 193:1388-93
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Grin, Boris; Loeb, Stacy; Roehl, Kim et al. (2015) A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease. BJU Int 115:101-5
Helenowski, Irene B; Demirtas, Hakan (2014) Multiple imputation of continuous data via a semiparametric probability integral transformation. J Biopharm Stat 24:359-77
Venkatasubramanian, Palamadai N; Brendler, Charles B; Plunkett, Beth A et al. (2014) Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study. Prostate 74:326-35
Adams, Daniel L; Martin, Stuart S; Alpaugh, R Katherine et al. (2014) Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A 111:3514-9
Ai, J; Pascal, L E; O'Malley, K J et al. (2014) Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. Oncogene 33:2286-94
Pavese, Janet M; Ogden, Irene M; Voll, Eric A et al. (2014) Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS One 9:e102289
Kregel, Steven; Szmulewitz, Russell Z; Vander Griend, Donald J (2014) The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate 74:1530-43
Wu, L; Runkle, C; Jin, H-J et al. (2014) CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene 33:504-13

Showing the most recent 10 out of 160 publications